Getting Ahead Of PFAS Risk In Pharmaceutical Manufacturing

Regulatory exemptions for essential PFAS uses in pharmaceuticals can create a false sense of security. Reporting duties, wastewater and solid waste obligations, CERCLA liability, and a major producer's exit from fluorinated materials manufacturing all carry consequences that exemptions do not cover.

Meanwhile, many PFAS uses cannot be swapped out without extensive testing, requalification, and regulatory review. The argument here favors a phased, science-based approach built on a clear picture of where PFAS enter and leave operations, including routes a conventional materials inventory may miss. It also considers how to separate essential uses from avoidable exposure.

Read on to weigh these pressures and decide where action matters most.